2023-04-25 07:36:00 ET
- Pre-commercial-stage biopharmaceutical company focused on oncology, BioLineRx ( NASDAQ: BLRX ) received formal notice from Nasdaq that the company has regained compliance with the minimum bid price requirement.
- The company was notified on November 2, 2022, that its ADSs had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
- From April 10, 2023 through April 21, 2023, a period of 10 consecutive trading days, the closing bid price of the company's ADSs was greater than $1.00 per share.
For further details see:
BioLineRx regains Nasdaq compliance